Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.
Pfizer (NYSE: PFE) enjoyed a record year in 2022. The big drugmaker's revenue topped $100 billion. Its earnings per share soared 42% to $5.47, which translates to nearly $31.4 billion in profits. Both top- and bottom-line numbers set all-time highs.